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Stroke is a clinical syndrome with diverse causes and mechanisms. Historically, reliance on
clinical diagnosis and exclusion of intracerebral hemorrhage and other nonstroke structural
pathologies by CT alone has produced highly heterogeneous trial populations; as a result,
any treatment effect has likely been obscured by the random noise of the many patients in
whom no relevant biological target exists, a strategy that greatly inflates sample sizes.1
Advances in brain and vascular imaging have driven the recent wave of positive clinical trials
investigating reperfusion therapies in acute ischemic stroke, allowing the identification of
patients with relevant therapeutic targets, such as intracranial large artery occlusion, clini-
cally meaningful volumes of potentially reversible tissue hypoperfusion (the ischemic
penumbra), and small volumes of irreversible tissue damage (the ischemic core). Combi-
nations of angiographic and perfusion imaging, primarily using CT, allow pathophysiologic
characterization of patients. The adoption of rigorous imaging selection in clinical trials
based on the concept of treatment-related acute imaging targets2 has allowed treatment
effects to be demonstrated with achievable sample sizes, and validates the precision medicine
concept in acute stroke.3
Further information to inform future clinical trial design is presented in this issue ofNeurology®
by Tian et al.4 on behalf of the International Stroke Perfusion Imaging Registry (INSPIRE).
The publication details CT perfusion findings, intracranial vessel occlusion site, and clinical
outcomes in a much broader range of acute stroke patients than that which participated in
recent clinical trials.
The analysis is motivated by the changing landscape and needs for clinical trials. Recent
endovascular thrombectomy trials have included predominantly patients with occlusion of
the first segment of the middle cerebral artery (MCA) or the intracranial internal carotid
artery,5 and in many countries this now constitutes the standard of care for such patients.
Future trials in these patients face the challenge of demonstrating additive treatment effect
on a background of continually advancing endovascular treatment. Clinical outcomes are
well-characterized only in the subgroup of patients enrolled in recent trials, however, and
the perfusion characteristics of trial participants predominantly reflect selection criteria
that include clinical severity, CT features such as the Alberta Stroke Program Early CT
Score (ASPECTS), and specific perfusion imaging requirements that only partially rep-
resent the clinical spectrum presenting to hospitals. More distal occlusions, or those in
other vascular territories such as the posterior cerebral artery, will likely constitute an
important target population for future trials, particularly for thrombolytic trials, and data
on outcomes related to these non-thrombectomy populations—which constituted more
than one third of the INSPIRE population—are valuable. Distal MCA occlusions and
posterior circulation events may have substantial neurologic deficit and are commonly
disabling, and these data from INSPIRE may also inform clinical decisions pending further
randomized trial data, since advances in endovascular treatment make such sites in-
creasingly amenable to intervention.
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Biomarkers may be of utility in phase 2 clinical trials where
conventional 90-day disability outcomes may be of limited
value due to small sample size. The INSPIRE investigators
present data on imaging indices such as infarct volume,
penumbral salvage, reperfusion, and recanalization that
may offer greater power than clinical measures.
Registry data have inherent limitations that should be borne in
mind. Information on the treatment effect of IV thrombolysis
as presented in the article must be regarded with particular
caution. Routinely captured factors such as stroke severity and
patient age may explain treatment decisions to only a limited
extent, particularly in less severe cases,6 and investigators had
access to angiographic and perfusion data, which are inter-
preted differently by different physicians.7 The central pro-
cessing of perfusion data using a common platform is
appropriate in a study, but such uniformity may be more
challenging to achieve in future trials. Different software
platforms may yield different findings. Patients were selected
if within a conventional time window for IV thrombolysis
(<4.5 hours from onset) with alteplase, but longer time
windows are of increasing interest as data accrue for late
window thrombolysis, and the thrombolytic agent of choice
may change if promising trials of tenecteplase lead to change
in clinical practice.8–10 Nonetheless, INSPIRE provides data
that will inform future clinical trial design in the acute stroke
field.
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